Renal physiology

Continuous Renal Replacement Therapy Market to Hit $1.4 Billion by 2025: Global Market Insights, Inc.

Retrieved on: 
Tuesday, October 8, 2019
Health sciences, Medicine, Branches of biology, Renal physiology, Ultrafiltration, Membrane technology, Renal replacement therapy, Hemofiltration, Therapy, Kidney

SELBYVILLE, Del., Oct. 8, 2019 /PRNewswire/ -- The Global Continuous Renal Replacement Therapy Market is poised to cross USD 1.4 billion by 2025; according to a new research report by Global Market Insights, Inc.

Key Points: 
  • SELBYVILLE, Del., Oct. 8, 2019 /PRNewswire/ -- The Global Continuous Renal Replacement Therapy Market is poised to cross USD 1.4 billion by 2025; according to a new research report by Global Market Insights, Inc.
  • The Slow Continuous Ultrafiltration (SCUF) segment of the continuous renal replacement therapy market will witness around 4% growth during the forecast time frame.
  • The Asia Pacific continuous renal replacement therapy market held around 19.5% revenue share in 2018.
  • The aforementioned factors coupled with rising government initiatives will positively impact the continuous renal replacement therapy market in Asia Pacific.

Global Urine Flow Meters Market 2019-2023 | Favorable Reimbursement Scenario to Boost Growth | Technavio

Retrieved on: 
Tuesday, September 10, 2019
Medical Supplies, Other Health, Diabetes, Pharmaceutical, Insurance, Medical devices, Practice Management, Hospitals, General Health, Professional services, Clinical trials, Cardiology, Surgery, Health, Renal physiology, Urine, Urine flow rate, Forecast period, Flow measurement, Assumption, Branches of biology

The global urine flow meters market size is poised to reach USD 22.92 million by 2023, according to a new report by Technavio, progressing at a CAGR of over 6% during the forecast period.

Key Points: 
  • The global urine flow meters market size is poised to reach USD 22.92 million by 2023, according to a new report by Technavio, progressing at a CAGR of over 6% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20190910005677/en/
    Technavio has published a new market research report on the global urine flow meters market from 2019-2023.
  • In addition, the presence of a favorable reimbursement scenario is anticipated to further boost the urine flow meters market during the forecast period.
  • The absence of substitute devices for performing uroflowmetry is a major advantage for the growth of the global urine flow meters market.

New Publication Highlights Transient Increases in Creatinine or Tubular Injury Markers in Heart Failure Patients Should Not Dissuade Use of Ultrafiltration

Retrieved on: 
Thursday, August 8, 2019
Branches of biology, Medicine, Clinical medicine, Renal physiology, Kidney diseases, Creatinine, Guanidines, Metabolism, Renal function, Biomarker, Diuretic, Kidney

The study supports that increases in serum creatinine should not be the major factor to dissuade decongestion by ultrafiltration or diuretics in patients where a therapeutic advantage may exist.

Key Points: 
  • The study supports that increases in serum creatinine should not be the major factor to dissuade decongestion by ultrafiltration or diuretics in patients where a therapeutic advantage may exist.
  • Even if creatinine worsened and tubular biomarkers increased, renal function usually recovered by 60 days.
  • Thus, changes in serum creatinine or kidney injury biomarkers should be discouraged as a surrogate endpoint in heart failure trials.
  • Study authors concluded that modest or transient increases in creatinine levels, or increases in renal tubule injury biomarkers were outweighed by the benefits of decongestion, which aligns with the review conducted by Drs.

Researchers Find More than Half of Patients with Newly Abnormal Kidney Function Tests are Not Getting Timely Follow-up Testing

Retrieved on: 
Tuesday, July 16, 2019
Branches of biology, Anatomy, Medical specialties, Kidney diseases, Organ failure, Renal physiology, RTT, Blood tests, Creatinine, Renal function, Chronic kidney disease, Epidermal growth factor receptor

"We sought to determine how frequently gaps in timely follow-up of abnormal creatinine/eGFR lab test results occur and to identify potential reasons for those gaps.

Key Points: 
  • "We sought to determine how frequently gaps in timely follow-up of abnormal creatinine/eGFR lab test results occur and to identify potential reasons for those gaps.
  • The eGFR test is the best way to estimate the level of kidney function and determine what further tests are needed.
  • The program serves as a back-up system to notify patients when they are overdue for follow-up of an abnormal creatinine/eGFR test.
  • African Americans are about 3 times more likely than Whites to develop end-stage kidney disease (ESKD or kidney failure).

The 2019 Creatinine Test Market: Global Industry Analysis, Trends, Market Size, and Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Health, Pharmaceutical, Renal physiology, Statistical forecasting, Creatinine, Guanidines, Metabolism, Forecasting

The "Creatinine Test Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Creatinine Test Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The report predicts the global creatinine test market to grow with a CAGR of 5.30%% over the forecast period from 2019-2025.
  • The report on the creatinine test market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global creatinine test market over the period of 2017 to 2025.
  • Complete coverage of all the segments in the creatinine test market to analyze the trends, developments in the global market and forecast of market size up to 2025.

Safety of Linagliptin for Adults with Type 2 Diabetes Who Have High Risk of Cardiovascular and/or Renal Disease Examined in CARMELINA

Retrieved on: 
Tuesday, June 11, 2019
RTT, Kidney diseases, Branches of biology, Chemical compounds, Organic compounds, Renal physiology, Guanidines, Eli Lilly and Company, Creatinine, Cardiovascular disease, Kidney, Albuminuria

Cardiovascular disease is a major risk factor and the leading cause of death for people living with T2D.

Key Points: 
  • Cardiovascular disease is a major risk factor and the leading cause of death for people living with T2D.
  • The participants had A1C levels of 6.5% to 10.0%, high CV risk (history of vascular disease and urine-albumin creatinine ratio [UACR] >200 mg/g) and a high renal risk (reduced eGFR and micro- or macroalbuminuria).
  • In the linagliptin group, 434 out of 3494 participants (12.4%) had a heart attack, stroke or died due to cardiovascular disease.
  • "This data is particularly important because it proves categorically the cardiovascular and kidney safety of linagliptin in those with type 2 diabetes who are at a high cardiovascular risk when some degree of kidney disease is associated.

First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy

Retrieved on: 
Tuesday, May 21, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Branches of biology, Medical specialties, Endocrine system, Peptide hormones, Endocrinology, RTT, Renal physiology, Renin, Chronic kidney disease, Aldosterone, Angiotensin, ACE inhibitor

View the full release here: https://www.businesswire.com/news/home/20190520005695/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190520005695/en/
    Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun.
  • The study will evaluate the potential of Veltassa to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2.
  • The DIAMOND study is designed to further support the use of Veltassa to effectively control high blood potassium levels, thereby enabling optimal RAASi therapy in HF patients.
  • RAASi therapy has been shown to improve cardiovascular and renal outcomes and is proven to prolong survival and reduce hospitalisation.

Motegrity™ (prucalopride), the Only Serotonin-4 Receptor Agonist for Adults with Chronic Idiopathic Constipation (CIC), is Now Available in the United States

Retrieved on: 
Tuesday, April 2, 2019
Drugs, Branches of biology, Neurochemistry, Renal physiology, RTT, Chloroarenes, Guanidines, Antidepressants, Creatinine, Serotonin, Renal function, Ketamine

Motegrityis a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation in adults.

Key Points: 
  • Motegrityis a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation in adults.
  • Patients with severe renal impairment (creatinine clearance (CrCL) less than 30 mL/min): recommended oral dose regimen is 1 mg once daily.
  • A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established.
  • Takeda has maintained a strong and growing commitment to the United States for more than 50 years.

Creatinine Measurement - Global Market Outlook (2017-2026) - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2019
Health, Biotechnology, Hospitals, Medical devices, Branches of biology, Medicine, Anatomy, Renal physiology, Creatinine, Guanidines, Metabolism, Nephrology, RTT, Biomarker, Kidney

The "Creatinine Measurement - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Creatinine Measurement - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • According to this report, the Global Creatinine Measurement market accounted for $330.9 million in 2017 and is expected to reach $745 million by 2026 growing at a CAGR of 9.4% during the forecast period.
  • However, often changing regulatory policies and recognition of novel renal dysfunction biomarkers are hampering the market growth.
  • These benefits are liable for the growing acceptance of the blood/serum sample for the measurement of creatinine levels.

Global Creatinine Measurement Market Outlook 2017-2018 & 2026: Market Accounted for $330.90 Million in 2017 and is Expected to Reach $745.00 Million by 2026

Retrieved on: 
Tuesday, February 5, 2019
Branches of biology, Renal physiology, Medicine, Biology, Creatinine, Guanidines, Metabolism, Kidney, Renal function, Biomarker, Geriatrics

The "Creatinine Measurement - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Creatinine Measurement - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Global Creatinine Measurement market accounted for $330.90 million in 2017 and is expected to reach $745.00 million by 2026 growing at a CAGR of 9.4% during the forecast period.
  • The growing renal functioning disorder and increasing geriatric population are driving the market.
  • However, often changing regulatory policies and recognition of novel renal dysfunction biomarkers are hampering the market growth.